Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6607720

Title:Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction
Inventors:Xiao, Yong-Fu; Wayland, MA, USA
Morgan, James P.; Newton Centre, MA, USA
Summary:Described herein are novel genetically altered primordial embryonic stem cells and the nucleotides encoding specific products that are expressed in situ. The invention relates to genetically altered mammalian embryonic stem cells whose living descendent progeny have an altered genomic DNA, and which may be maintained in-vitro as a stable cell line. Therapeutic applications focus on methods by which such cells may be used to improve cardiac function in a living subject after myocardial infarction. Further detailed are the steps by which such cells may be transplanted as active, mitotic cells to an infarcted myocardial area using any surgical procedure. Claims of the invention include the means by which these genetically altered cells will differentiate in-situ, after transplantation at a chosen anatomic site within the heart of the subject, thereby causing a regeneration of myocardocytes and an improvement in cardiac function for the subject.
Abstract:The present invention provides genetically altered mammalian embryonic stem cells, their living descendent progeny having an altered genomic DNA, and therapeutic methods using these cells for improving cardiac function in a living subject after myocardial infarction. The genetically altered embryonic stem and progenitor cells may be maintained in-vitro as a stable cell line; and transplanted as active, mitotic cells to an infarcted area of the myocardial using any surgical procedure. After transplantation at a chosen anatomic site within the heart of the subject, these genetically altered cells will differentiate in-site, cause a regeneration of myocardocytes, and will effect a marked improvement in cardiac function for the subject.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6607720
Application Number:US2000000684679
Date Filed:07/10/2000
Date Published:19/08/2003
Assignee:None


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021